Revelation Biosciences Presented Data Showing Pretreatment With Gemini, Improved Kidney Function With Reduced Serum Blood Urea Nitrogen And Creatinine, Urine C-reactive Protein, And Acute Kidney Injury-Related Inflammation
Revelation Biosciences Presented Data Showing Pretreatment With Gemini, Improved Kidney Function With Reduced Serum Blood Urea Nitrogen And Creatinine, Urine C-reactive Protein, And Acute Kidney Injury-Related Inflammation
Revelation Biosciences提供的數據顯示，使用Gemini進行預治療，降低血清尿素氮和肌酐，尿液C反應蛋白，改善腎臟功能，以及與急性腎損傷相關的炎症
Gemini is the company's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) for systemic administration. It is being developed as a potential therapy for prevention and treatment of hospital acquired infection (REVTx-100 program) and as a potential treatment for acute and chronic organ disease including prevention of acute kidney injury (REVTx-300 program), myocarditis, and chronic kidney disease (CKD).
Gemini是該公司專有的磷酸化六酰二糖（PHAD）配方，用於全身給藥。它被開發爲預防和治療醫院獲得性感染的潛在療法（revTX-100計劃），以及急性和慢性器官疾病的潛在治療方法，包括預防急性腎損傷（revTX-300計劃）、心肌炎和慢性腎臟病（CKD）。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。